Forbion, Fountain et al. in £23m series-B for Nerre Therapeutics

Alongside the new backers, existing investors Advent Life Sciences and Danish pharmaceutical group Novo also participated.

Nerre intends to use the fresh funding to support clinical trials of certain therapeutics the company is developing.

The round was led by Fountain, while Forbion and Orbimed co-led the series-B.

Company
Nerre is a biotechnology company developing treatments for common, chronic and debilitating conditions caused by neuronal hypersensitivity.

The business is based in Stevenage, having spun out of Glaxo Smith Kline in 2012.

People
Nerre Therapeutics– Mary Kerr (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Expansion
• UK / Ireland
• Advent International
• United Kingdom